Read by QxMD icon Read


Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo, Hans H Fischer, William Jacot, Alison K Conlin, Claudia Arce-Salinas, Irene L Wapnir, Christian Jackisch, Michael P DiGiovanna, Peter A Fasching, John P Crown, Pia Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H Lam, David Tesarowski, Melanie Smitt, Hannah Douthwaite, Stina M Singel, Charles E Geyer
BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy...
December 5, 2018: New England Journal of Medicine
Varun Chowdhry, Saveli Goldberg, Thomas F DeLaney, Gregory M Cote, Ivan Chebib, Jason Kim, Santiago A Lozano-Calderón, Karen De Amorim Bernstein
Introduction: Myxoid liposarcoma (MLS) is a subtype of liposarcoma characterized morphologically by lipomatous differentiation with a myxoid stroma. The purpose of this study was to review clinical and pathological information for patients treated for MLS at our institution to better understand neoadjuvant and adjuvant therapy. Materials and Methods: An institutional database of sarcomas was queried for patients who were treated for MLS at our institution between 1992 and 2013...
2018: Sarcoma
William T Tran, Charmaine Childs, Heidi Probst, Golnaz Farhat, Gregory J Czarnota
Guidelines from the American National Comprehensive Cancer Network recommend neoadjuvant chemotherapy to patients with locally advanced breast cancer (LABC) to downstage tumours before surgery. However, only a small fraction (15%-17%) of LABC patients achieve pathological complete response (pCR); that is, no residual tumour in the breast, after treatment. Measuring tumour response during neoadjuvant chemotherapy can potentially help physicians adapt treatment, thus potentially improving the pCR rate. Recently, imaging biomarkers that are used to measure the tumour's functional and biological features have been studied as pretreatment markers for pCR or as an indicator for intratreatment tumour response...
December 2018: Journal of Medical Imaging and Radiation Sciences
Binliang Liu, Tao An, Meiying Li, Zongbi Yi, Chunxiao Li, Xiaoying Sun, Xiuwen Guan, Lixi Li, Yanfeng Wang, Yuhui Zhang, Binghe Xu, Fei Ma, Yixin Zeng
BACKGROUND: An increasing number of cancer patients die of cardiovascular diseases. The cardiotoxicity of chemotherapy is particularly important in triple-negative breast cancer (TNBC) with limited therapeutic options. Cardiac autophagy is an important mechanism of cardiotoxicity. This research was aimed to investigate the cardiotoxicity of chemotherapy in TNBC, screen the susceptible population, and determine the relationship between cardiotoxicity and autophagy-related polymorphisms...
December 4, 2018: Cancer communications
Keiichiro Hatoyama, Yusuke Taniyama, Tadashi Sakurai, Chiaki Sato, Hiroshi Okamoto, Yu Onodera, Takashi Kamei
BACKGROUND: Funnel chest is the most common chest deformity, occurring in 0.06-0.3% of the general population. When it occurs concomitantly with esophageal cancer, it hinders intrathoracic surgery that is necessary for treatment. Although there are a few reports of esophagectomy performed in patients with funnel chest, simultaneous treatment of esophageal cancer and funnel chest with funnel chest surgery (Nuss method) and esophagectomy has not been reported. We report the first case of advanced esophageal cancer complicated by severe funnel chest that was treated using the Nuss method and radical thoracoscopic esophagectomy...
December 4, 2018: BMC Cancer
Hui Xie, Jinping Liu, Shiyou Yu, Yiding Chen, Min Zheng, Yongchuan Deng, Shu Wang, Jun Jiang, Yafen Li, Huiping Li, Hua Kang, Chunhui Zhang, Guo-Jun Zhang, Fengxi Su, Aiqun Cheng, Shui Wang
INTRODUCTION: Adjuvant docetaxel-based chemotherapy is frequently used in the treatment of operable early breast cancer (EBC). This study investigated patterns of docetaxel use in patients with EBC in real-world clinical practice in China. METHODS: This was a multicenter, prospective, observational study of Chinese women with operable breast cancer in tier 1 non-oncology-specific hospitals and other city hospitals in China. Adult Chinese female patients (≥ 18 years) with newly diagnosed breast cancer who underwent surgery and received docetaxel-containing adjuvant chemotherapy were eligible for inclusion...
December 3, 2018: Advances in Therapy
Guoming Hu, Feng Xu, Kefang Zhong, Shimin Wang, Qi Xu, Liming Huang, Pu Cheng
BACKGROUND: Systemic inflammatory response (SIR) plays important roles in initiation, promotion and progression of tumor. However, the prognostic role of preoperative circulating neutrophil-lymphocyte ratio (NLR) (known as a marker of SIR) in human primary bladder cancer (BC) undergoing radical cystectomy (RC) remains controversial. Hence, we performed this meta-analysis to better understand the role of preoperative circulating NLR in prognosis prediction for primary BC patients undergoing RC...
December 3, 2018: World Journal of Urology
Lieve G J Leijssen, Anne M Dinaux, Hiroko Kinutake, Liliana G Bordeianou, David L Berger
BACKGROUND: Although stage I colorectal cancer has an excellent prognosis after complete surgical resection, disease recurrence still occurs. This study aimed to assess prognostic risk factors in this early stage of disease. METHODS: All non-neoadjuvantly treated stage I colon (CC) and rectal (RC) patients who underwent a surgical resection between 2004 and 2015 were identified. Clinicopathological differences and long-term oncological outcomes were compared. RESULTS: CC patients (n = 433) were older and had more pre-existing comorbidities...
December 3, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Cristina Guarducci, Martina Bonechi, Matteo Benelli, Chiara Biagioni, Giulia Boccalini, Dario Romagnoli, Roberto Verardo, Rachel Schiff, C Kent Osborne, Carmine De Angelis, Angelo Di Leo, Luca Malorni, Ilenia Migliaccio
CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6 inhibitor palbociclib, and analyzed cell cycle-related markers by gene expression profiles (GEP) and western blot (WB). GEP showed high molecular heterogeneity among the models, with E2F targets being significantly enriched both during treatment and at the time of resistance...
2018: NPJ Breast Cancer
Takashi Kijima, Hiroshi Nakagawa, Masataka Shimonosono, Prasanna M Chandramouleeswaran, Takeo Hara, Varun Sahu, Yuta Kasagi, Osamu Kikuchi, Koji Tanaka, Veronique Giroux, Amanda B Muir, Kelly A Whelan, Shinya Ohashi, Seiji Naganuma, Andres J Klein-Szanto, Yoshiaki Shinden, Ken Sasaki, Itaru Omoto, Yoshiaki Kita, Manabu Muto, Adam J Bass, J Alan Diehl, Gregory G Ginsberg, Yuichiro Doki, Masaki Mori, Yasuto Uchikado, Takaaki Arigami, Narayan G Avadhani, Devraj Basu, Anil K Rustgi, Shoji Natsugoe
Background & Aims: Oropharyngeal and esophageal squamous cell carcinomas, especially the latter, are a lethal disease, featuring intratumoral cancer cell heterogeneity and therapy resistance. To facilitate cancer therapy in personalized medicine, three-dimensional (3D) organoids may be useful for functional characterization of cancer cells ex vivo . We investigated the feasibility and the utility of patient-derived 3D organoids of esophageal and oropharyngeal squamous cell carcinomas...
2019: Cellular and Molecular Gastroenterology and Hepatology
Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R Plimack, Lauren C Harshman, Evan Y Yu, Simon J Crabb, Sumanta Kumar Pal, Ajjai S Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D Galsky, Cora N Sternberg
Background: MIBC is an aggressive disease, with 5-year survival rates ranging from 36 to 48% for p T3/p T4/p N+tumors. Perioperative treatment can improve overall survival, with more robust evidence in favor of neoadjuvant chemotherapy. Few randomized studies have compared neoadjuvant and adjuvant therapy in bladder cancer. Consequently, it has been difficult to establish the benefit of adjuvant chemotherapy (AC) in MIBC. Methods: Data from patients with muscle invasive bladder cancer (>pT2) collected from 2005 to 2012 within the RISC data base (Retrospective International Study of Cancers of the Urothelial Tract) were evaluated...
2018: Frontiers in Oncology
Irma Soldevilla-Gallardo, Sevastian S Medina-Ornelas, Cynthia Villarreal-Garza, Enrique Bargalló-Rocha, Claudia Hs Caro-Sánchez, Rodrigo Hernández-Ramírez, Enrique Estrada-Lobato
Our study examines the association between two Positron Emission Mammography (PEM) semi-quantitative parameters: PUVmax (maximum uptake value) and LTB (lesion to background) baseline and the end of Neoadjuvant chemotherapy (NAC) with pathologic response in each of the following breast cancer subtype: Triple negative breast cancer (TPN), HER2-positive, and ER-positive/HER2-negative cancers. One-hundred and eight patients, 71 with invasive ductal carcinoma and 37 with infiltrating lobular carcinoma were evaluate with 18 F-FDG-PEM scans before and after of NAC...
2018: American Journal of Nuclear Medicine and Molecular Imaging
Kan Xue, Xiangji Ying, Zhaode Bu, Aiwen Wu, Zhongwu Li, Lei Tang, Lianhai Zhang, Yan Zhang, Ziyu Li, Jiafu Ji
Objective: To compare the effect of neoadjuvant chemotherapy (NACT) with adjuvant chemotherapy (ACT) using oxaliplatin plus S-1 (SOX) or capecitabine (CapeOX) on gastric cancer patients with D2 lymphadenectomy. Methods: This was a two-by-two factorial randomized phase II-III trial, and registered on ISRCTN registry (No. ISRCTN12206108). Locally advanced gastric cancer patients were randomized to neoadjuvant SOX, neoadjuvant CapeOX, adjuvant SOX, or adjuvant CapeOX arms...
October 2018: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Elizabeth Gourd
No abstract text is available yet for this article.
December 2018: Lancet Oncology
François Audenet, John P Sfakianos, Nikhil Waingankar, Nora H Ruel, Matthew D Galsky, Bertram E Yuh, Greg E Gin
OBJECTIVES: To investigate delays to neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) and their effect on outcomes in a large national registry of patients with localized muscle invasive bladder cancer. PATIENTS AND METHODS: Within the National Cancer Database (2004-2014), we identified 2,227 patients who underwent NAC and RC for cT2-T4aN0M0 urothelial carcinoma of the bladder. Times from diagnosis to treatments were tested for association with overall survival and pathologic outcomes, using Cox models, and restricted cubic splines regression...
November 30, 2018: Urologic Oncology
A Vallard, P Diao, M-A Garcia, G Pigné, N Vial, F Forest, M Peoc'h, J Langrand-Escure, N Magné
PURPOSE: There is paucity of data on rectal cancer with uncommon histologic types. The objective was to describe managements of care and outcomes in patients with rectal cancer of histologic types other than adenocarcinoma. MATERIAL AND METHODS: This monoinstitutional retrospective study included all patients with rectal cancer undergoing rectal radiotherapy. RESULTS: From 2004 to 2015, 744 patients were treated for rectal cancer, and ten had a histologic type other than adenocarcinoma...
November 30, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Hendrik Dapper, Iván Rodríguez, Stefan Münch, Jan C Peeken, Kai Borm, Stephanie E Combs, Daniel Habermehl
BACKGROUND: Neoadjuvant radio- or chemoradiation (nIRT) therapy is the standard treatment for loco-regional advanced rectal cancer patients of the lower or middle third. Currently, intensity modulated radiation therapy (IMRT) is not the recommended radiation technique even though IMRT has advantages compared to 3D-radiation regarding dose sparing to organs at risk like small bowel and urinary bladder. So far, the benefit of IMRT concerning the anal sphincter complex is not examined. With this study we intended to evaluate the dose distribution on the anal sphincters of rectal cancer patients treated with IMRT in comparison with 3D-techniques...
December 3, 2018: Radiation Oncology
Alexandr O Ivantsov
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer (OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental masses...
December 2018: Chinese Clinical Oncology
Jae Hyun Cho, Seik Kim, Yong Sang Song
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancy and is the seventh most common cancer among women worldwide. The primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT) is a standard treatment of advanced EOC. However, there are still several limitations, such as high recurrence rate and subsequent chemoresistance. To date, many studies have reported that neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) shows non-inferior survival outcome and is associated with less postoperative morbidity compared with PDS...
December 2018: Chinese Clinical Oncology
Tatiana V Gorodnova, Anna P Sokolenko, Ekatherina Kuligina, Igor V Berlev, Evgeny N Imyanitov
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages. Cytoreductive surgery is a backbone of EOC treatment. Wherever possible, EOC patients are subjected to primary debulking surgery (PDS) with the aim to remove all visible tumor lumps. Some patients cannot undergo PDS due to extensive disease spread and/or high risk of perioperative morbidity, therefore they are subjected to neoadjuvant chemotherapy (NACT) before the surgery...
December 2018: Chinese Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"